Thomas Ottoboni - Heron Therapeuti President
| HRTX Stock | USD 1.69 0.07 3.98% |
President
Dr. Thomas B. Ottoboni, Ph.D., is Senior Vice President Pharmaceutical and Preclinical Research and Development of the Company. Dr. Blake has more than 25 years of experience in clinical research and medical affairs. From January 2017 to November 2017, Dr. Blake served as Senior Vice President of Clinical, Medical, and Regulatory Affairs at BioDelivery Sciences International, Inc. From 2014 to 2016, Dr. Blake served as Chief Development Officer at Oxford BioMedica PLC. From 2007 to 2014, Dr. Blake served as Chief Medical Officer and Senior Vice President of Clinical Research and Development at Aeterna Zentaris Inc. Dr. Blake has also held various leadership positions in biopharmaceutical companies, including Cephalon, Inc. and SmithKline Beecham Pharmaceuticals Ltd. Over his career, Dr. Blake has contributed to more than 40 NDAs and sNDAs, including products for the treatment of pain such as Relafen, a nonsteroidal antiinflammatory drug that reduces hormones that cause pain and inflammation, and Fentora, an opioid pain medication. Other drugs that Dr. Blake was involved in developing include Kytril, Tenormin, Zestril, Paxil, Coreg, Havrix, Hycamtin, Famvir, Requip, Avandia and Provigil . Dr. Blake is qualified in medicine from the Royal Free Hospital School of Medicine, London University. He is a Fellow of the Royal College of Physicians, a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and a Fellow of the American College of Clinical Pharmacology. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 4242 Campus Point Court, San Diego, CA, United States, 92121 |
| Phone | 858 251 4400 |
| Web | https://www.herontx.com |
Heron Therapeuti Management Efficiency
The company has return on total asset (ROA) of (0.0231) % which means that it has lost $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.42 in 2024, whereas Return On Tangible Assets are likely to drop (0.52) in 2024. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 35.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.5 M in 2024.Similar Executives
| Found 4 records | PRESIDENT Age | ||
| Erin MD | Terns Pharmaceuticals | 53 | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Steven Perrin | Eledon Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0231 |
Heron Therapeuti Leadership Team
Elected by the shareholders, the Heron Therapeuti's board of directors comprises two types of representatives: Heron Therapeuti inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heron. The board's role is to monitor Heron Therapeuti's management team and ensure that shareholders' interests are well served. Heron Therapeuti's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heron Therapeuti's outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD D, Executive Officer | ||
| Barry PharmD, Chairman CEO | ||
| Lisa Peraza, VP Officer | ||
| Chris Storgard, Chief Officer | ||
| Kimberly Manhard, Independent Director | ||
| Sean Ristine, Vice President - Human Resources | ||
| Michael Mathews, Senior Vice President - Pain Franchise | ||
| John Poyhonen, Independent Director | ||
| Thomas Ottoboni, Senior Vice President - Pharmaceutical and Preclinical Research and Development | ||
| Brett Fleshman, Chief Officer | ||
| David Szekeres, Senior Vice President General Counsel, Business Development, Corporate Secretary | ||
| Ira Duarte, Executive CFO | ||
| Ryan Craig, Vice Marketing | ||
| Craig Collard, CEO Director | ||
| Jeff Cohn, Assistant Director | ||
| Robert Sullivan, Senior Operations |
Heron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heron Therapeuti a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -24.09 | ||||
| Return On Asset | -0.0231 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 364.4 M | ||||
| Shares Outstanding | 152.1 M | ||||
| Shares Owned By Insiders | 0.71 % | ||||
| Shares Owned By Institutions | 81.56 % | ||||
| Number Of Shares Shorted | 27.54 M | ||||
| Price To Earning | (5.15) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.